A “Mechanical Force” Immune Signal Emerges in the Alzheimer’s Choroid Plexus: Expansion of TTN-Positive Macrophages

The brain and body are not separated by a simple, sealed wall. The choroid plexus, located within the brain’s ventricles, produces cerebrospinal fluid while regulating peripheral immune signals and the entry of cells into the central nervous system. A Yale University team has now identified a distinctive population of macrophages in the human choroid plexus, suggesting that immune activity at this boundary may be driven not only by inflammatory molecules but also by the tension, flow, and tissue stiffness experienced by cells.

Using postmortem human tissue, the researchers created single-nucleus and spatial transcriptomic atlases comparing Alzheimer’s disease samples with unaffected controls. The publicly available data include 9 independently processed single-nucleus RNA-sequencing datasets and 4 spatial transcriptomic samples. The latter preserve the tissue locations of gene expression at a resolution of approximately 10 micrometers, allowing the team not only to identify cell types but also to observe their distribution across choroid plexus folds and among neighboring cells.

The atlas’s most striking finding was a TTN-positive population accounting for approximately 21.8% of the macrophages analyzed. TTN, commonly known as “connectin” or titin in muscle research, is one of the largest proteins in the human body and helps sarcomeres withstand and recover from deformation. Its presence in choroid plexus macrophages therefore raises the question of whether immune cells also use this structural system to sense their physical environment. The team further confirmed the TTN signal using isoform-specific RT-qPCR, protein immunofluorescence, and single-molecule FISH, reducing the possibility of misidentification caused by reliance on a single sequencing method.

These cells were also enriched for genes associated with cytoskeletal remodeling, phagocytosis, autophagy, inflammation, and oxidative stress. In Alzheimer’s disease tissue, the proportion of TTN-positive macrophages was increased, while cellular aging signals and mechanotransduction features linked to MEF2 transcription factors were also stronger. Computational analysis further suggested that ligand–receptor communication between these cells and epithelial, endothelial, and stromal cells was reduced, indicating a state of gradually becoming disconnected from their original tissue environment.

These findings extend the view of immune dysregulation in Alzheimer’s disease from microglia within the brain parenchyma to the blood–cerebrospinal fluid interface. However, transcriptional features and spatial proximity can show only associations. They cannot demonstrate that TTN causes macrophage expansion, nor can they determine whether these cells drive disease progression, respond to existing damage, or do both. The study also used a limited number of postmortem samples, making it difficult to rule out the effects of age, postmortem tissue changes, and individual variation.

Background

In recent years, neurodegeneration research has increasingly viewed the meninges, choroid plexus, perivascular spaces, and lymphatic drainage as an interconnected boundary system. Different pathways may jointly affect immune-cell trafficking, inflammatory signals, and the clearance of metabolic waste. However, the choroid plexus macrophage atlas does not demonstrate that altering any of these pathways can improve cognition or disease progression, nor does it directly support existing brain-drainage interventions.

To turn “tissue mechanics” into a therapeutic lever, the next step will be to directly manipulate TTN or related mechanical signals in living cells and animal models, measure macrophage adhesion, migration, deformation, and immunoregulatory functions, and then determine whether communication with barrier cells can be restored. For now, the more cautious interpretation is that this publicly testable human atlas offers a clue to a new mechanism, rather than identifying a new therapeutic target for Alzheimer’s disease.